Oryzon Genomics SA's total assets for Q2 2024 were €110.67M, an increase of 10.34% from the previous quarter. ES:ORY total liabilities were €24.16M for the fiscal quarter, a 4.26% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.